AI-driven biotech Fathom Therapeutics secures $47 million Series A funding and rebrands from Atommap

Fathom Therapeutics, the company formerly known as Atommap, announced that it has closed a $47 million Series A financing round. The capital raise will support the firm’s effort to combine artificial intelligence with physics‑based modeling to accelerate drug discovery.

The startup was founded by Huafeng Xu together with Yujie Wu and Jesus Izaguirre. Their approach builds on early work by billionaire scientist David Shaw, who in the early 2000s built supercomputers to study molecular behavior.

By rebranding as Fathom Therapeutics, the team signals a broader ambition to apply its computational platform across a wider range of therapeutic targets, leveraging the new funding to expand its research programs and talent pool.